OSIVAX Belgique SRL
8.7 FTEOSIVAX Belgique reported total assets of €17.0m at the end of the 2025 financial year (annual accounts filed with the NBB on 14 Oct 2026), with 8.7 full-time equivalents.
By total assets for 2025, OSIVAX Belgique ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of OSIVAX Belgique shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +22 % Total assets +17 % Headcount (avg FTE) +85 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
OSIVAX Belgique's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 14 Oct 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 26 Aug 2024
- Year ended 31 Dec 2022filed on 19 Sep 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
OSIVAX Belgique's financial analysis
- Solvency78.6%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of OSIVAX Belgique
OSIVAX Belgique's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0707.772.871
- VAT number
- BE0707772871
- Peppol
- Registered · 0208:0707772871 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Oct 2018
- Registered office
- 4031 Liège
- Size
- Micro · 8.7 FTE
- Latest accounts
- 2025 · filed on 14 Oct 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
OSIVAX Belgique (SRL) has been based in Liège since 2018, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €2.84m and equity of €13.3m; its revenue is not published. With 8.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 78.6%, above the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to OSIVAX Belgique
Companies in the same business, of comparable size and area, outside its group.
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- Augustine Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €30.9m
- iTeos Belgium Research and experimental development on natural sciences and engineering Charleroi · balance sheet €46.3m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- Aboleris Holdco Research and experimental development on natural sciences and engineering Charleroi · balance sheet €14.8m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
Frequently asked questions about OSIVAX Belgique
What is the revenue of OSIVAX Belgique?
OSIVAX Belgique files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of OSIVAX Belgique?
In Belgium, the VAT number is the company number prefixed with BE: BE0707772871 for OSIVAX Belgique, if the company is VAT-registered. Its company number (CBE) is 0707.772.871.
Where is the registered office of OSIVAX Belgique?
According to the CBE register, the registered office of OSIVAX Belgique is in 4031 Liège.
What is the equity of OSIVAX Belgique?
At the close of the 2025 financial year, the equity of OSIVAX Belgique amounts to 13,338,809 €, a solvency of 78.6% of total assets.
How many people work at OSIVAX Belgique?
8.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages OSIVAX Belgique?
The register lists 2 active mandates at OSIVAX Belgique. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is OSIVAX Belgique within its sector?
By total assets for 2025, OSIVAX Belgique ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of OSIVAX Belgique
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →